Insider Selling: VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells 11,000 Shares of Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 11,000 shares of the stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $16.71, for a total value of $183,810.00. Following the sale, the insider owned 3,538,961 shares in the company, valued at approximately $59,136,038.31. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total transaction of $20,260.03.

VanEck Biotech ETF Stock Performance

BBH stock traded up $1.14 during trading on Tuesday, hitting $203.43. The company had a trading volume of 7,033 shares, compared to its average volume of 5,972. The firm has a 50-day moving average price of $193.41 and a 200-day moving average price of $192.04. VanEck Biotech ETF has a 12 month low of $155.45 and a 12 month high of $212.54.

Hedge Funds Weigh In On VanEck Biotech ETF

Hedge funds have recently added to or reduced their stakes in the company. Empowered Funds LLC bought a new stake in VanEck Biotech ETF during the 4th quarter worth about $38,000. Flagship Harbor Advisors LLC acquired a new stake in shares of VanEck Biotech ETF during the 4th quarter worth approximately $47,000. Allworth Financial LP grew its position in shares of VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after buying an additional 306 shares during the period. Fifth Third Bancorp bought a new stake in shares of VanEck Biotech ETF during the first quarter worth approximately $127,000. Finally, Huntington National Bank bought a new stake in shares of VanEck Biotech ETF during the fourth quarter worth approximately $132,000. Institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.